GeneDx Holdings Corp. - Class A Common Stock (WGS)

GeneDx (WGS) Q3 2025 Earnings Call Transcript

GeneDx Q3 2025 earnings crush estimates with 52% revenue growth. Strong exome/genome test demand and raised 2025 guidance fuel investor optimism.

GeneDx stock shows strong growth momentum with 600% EPS growth and a bullish technical setup, signaling a potential breakout for investors.

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

GeneDx (WGS) shows explosive growth with 600% EPS growth and a strong technical uptrend, making it a top high-growth momentum stock for investors.

It continued to ride high on its solid second-quarter performance.

There's nothing like a crushing double beat on quarterly results to give some life to a stock.

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

GeneDx Holdings Corp (WGS) shows strong earnings & revenue growth, positive analyst revisions, and solid technicals, making it a high-growth momentum stock with breakout potential.

With major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories?